$EYEN
EYENOVIA, INC.

2024 Q4 Form 10-Q Financial Statement

#000141057824001894 Filed on November 12, 2024

View on sec.gov

Income Statement

Concept 2024 Q4 2024 Q3
Revenue $1.625K
YoY Change 35.64%
Cost Of Revenue $132.5K
YoY Change 10961.94%
Gross Profit -$130.9K
YoY Change
Gross Profit Margin -8055.2%
Selling, General & Admin $3.729M
YoY Change 26.84%
% of Gross Profit
Research & Development $3.472M
YoY Change -2.97%
% of Gross Profit
Depreciation & Amortization $287.5K
YoY Change -10.16%
% of Gross Profit
Operating Expenses $7.201M
YoY Change 10.44%
Operating Profit -$7.332M
YoY Change 12.45%
Interest Expense -$557.1K
YoY Change -182.02%
% of Operating Profit
Other Income/Expense, Net -$555.9K
YoY Change -32.08%
Pretax Income -$7.888M
YoY Change 7.46%
Income Tax
% Of Pretax Income
Net Earnings -$7.888M
YoY Change 7.48%
Net Earnings / Revenue -485406.34%
Basic Earnings Per Share -$0.11
Diluted Earnings Per Share -$0.11
COMMON SHARES
Basic Shares Outstanding 86.44M 64.06M
Diluted Shares Outstanding 69.56M

Balance Sheet

Concept 2024 Q4 2024 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $7.188M
YoY Change -65.27%
Cash & Equivalents $7.200M
Short-Term Investments
Other Short-Term Assets $1.108M
YoY Change -77.3%
Inventory $2.967M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $11.69M
YoY Change -55.94%
LONG-TERM ASSETS
Property, Plant & Equipment $2.752M
YoY Change -22.06%
Goodwill
YoY Change
Intangibles $6.123M
YoY Change 188.42%
Long-Term Investments
YoY Change
Other Assets $955.5K
YoY Change 38.48%
Total Long-Term Assets $11.11M
YoY Change 33.29%
TOTAL ASSETS
Total Short-Term Assets $11.69M
Total Long-Term Assets $11.11M
Total Assets $22.80M
YoY Change -34.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.574M
YoY Change 10.37%
Accrued Expenses $4.741M
YoY Change 130.13%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $9.429M
YoY Change 213.27%
Total Short-Term Liabilities $15.78M
YoY Change 141.02%
LONG-TERM LIABILITIES
Long-Term Debt $2.141M
YoY Change -80.71%
Other Long-Term Liabilities $1.153M
YoY Change -19.95%
Total Long-Term Liabilities $3.294M
YoY Change -73.73%
TOTAL LIABILITIES
Total Short-Term Liabilities $15.78M
Total Long-Term Liabilities $3.294M
Total Liabilities $19.08M
YoY Change -0.05%
SHAREHOLDERS EQUITY
Retained Earnings -$175.4M
YoY Change 27.54%
Common Stock $8.638K
YoY Change 101.35%
Preferred Stock
YoY Change
Treasury Stock (at cost) $0.00
YoY Change -100.0%
Treasury Stock Shares
Shareholders Equity $3.719M
YoY Change
Total Liabilities & Shareholders Equity $22.80M
YoY Change -34.62%

Cashflow Statement

Concept 2024 Q4 2024 Q3
OPERATING ACTIVITIES
Net Income -$7.888M
YoY Change 7.48%
Depreciation, Depletion And Amortization $287.5K
YoY Change -10.16%
Cash From Operating Activities -$5.944M
YoY Change 1.78%
INVESTING ACTIVITIES
Capital Expenditures $1.630K
YoY Change -99.72%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$1.630K
YoY Change -99.9%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.83M
YoY Change 0.49%
NET CHANGE
Cash From Operating Activities -5.944M
Cash From Investing Activities -1.630K
Cash From Financing Activities 10.83M
Net Change In Cash 4.887M
YoY Change 51.31%
FREE CASH FLOW
Cash From Operating Activities -$5.944M
Capital Expenditures $1.630K
Free Cash Flow -$5.945M
YoY Change -7.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Central Index Key
EntityCentralIndexKey
0001682639
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
CY2024Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
86375958
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
45553026
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38365
dei Entity Registrant Name
EntityRegistrantName
EYENOVIA, INC.
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
47-1178401
dei Entity Address Address Line1
EntityAddressAddressLine1
295 Madison Avenue, Suite 2400
dei Entity Address City Or Town
EntityAddressCityOrTown
NEW YORK
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10017
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
393-6684
dei Security12b Title
Security12bTitle
Common Stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
EYEN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
86441611
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7188129
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14849057
CY2024Q3 us-gaap Inventory Net
InventoryNet
2967256
CY2023Q4 us-gaap Inventory Net
InventoryNet
109798
CY2024Q3 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
408832
CY2023Q4 eyen Deferred Clinical Supply Costs
DeferredClinicalSupplyCosts
4256793
CY2024Q3 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
137594
CY2023Q4 eyen License Fee And Expense Reimbursements Receivables
LicenseFeeAndExpenseReimbursementsReceivables
123833
CY2023Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
1506
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
987754
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1365731
CY2024Q3 us-gaap Assets Current
AssetsCurrent
11689565
CY2023Q4 us-gaap Assets Current
AssetsCurrent
20706718
CY2024Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2752404
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3374384
CY2024Q3 eyen Security Deposits
SecurityDeposits
197526
CY2023Q4 eyen Security Deposits
SecurityDeposits
197168
CY2024Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
6122945
CY2023Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
2122945
CY2024Q3 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
46520
CY2024Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1275690
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1666718
CY2024Q3 eyen Equipment Deposits
EquipmentDeposits
711441
CY2023Q4 eyen Equipment Deposits
EquipmentDeposits
711441
CY2024Q3 us-gaap Assets
Assets
22796091
CY2023Q4 us-gaap Assets
Assets
28779374
CY2024Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1573940
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1753172
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1656832
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1658613
CY2024Q3 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
2518086
CY2023Q4 eyen Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
287928
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
604647
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
501250
CY2024Q3 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
562711
CY2023Q4 eyen Notes Payable Unamortized Discount Current
NotesPayableUnamortizedDiscountCurrent
503914
CY2024Q3 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
6168593
CY2023Q4 us-gaap Short Term Bank Loans And Notes Payable
ShortTermBankLoansAndNotesPayable
5329419
CY2024Q3 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
72467
CY2023Q4 eyen Convertible Notes Payable Unamortized Discount Current
ConvertibleNotesPayableUnamortizedDiscountCurrent
0
CY2024Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
3260866
CY2024Q3 us-gaap Liabilities Current
LiabilitiesCurrent
15782964
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
9530382
CY2024Q3 eyen Accrued Expenses And Other Liabilities Noncurrent
AccruedExpensesAndOtherLiabilitiesNoncurrent
316275
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
836434
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1292667
CY2024Q3 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
0
CY2023Q4 eyen Notes Payable Unamortized Discount Noncurrent
NotesPayableUnamortizedDiscountNoncurrent
448367
CY2024Q3 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
637500
CY2023Q4 us-gaap Other Long Term Notes Payable
OtherLongTermNotesPayable
4355800
CY2024Q3 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
163051
CY2023Q4 eyen Convertible Notes Payable Unamortized Discount Noncurrent
ConvertibleNotesPayableUnamortizedDiscountNoncurrent
398569
CY2024Q3 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
1503615
CY2023Q4 us-gaap Convertible Long Term Notes Payable
ConvertibleLongTermNotesPayable
4601431
CY2024Q3 us-gaap Liabilities
Liabilities
19076788
CY2023Q4 us-gaap Liabilities
Liabilities
19780280
CY2024Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
6000000
CY2024Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2024Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
86375958
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
45553026
CY2024Q3 us-gaap Common Stock Value
CommonStockValue
8638
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
4555
CY2024Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
179065877
CY2023Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
154486098
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175355212
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-145491559
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3719303
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8999094
CY2024Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
22796091
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
28779374
CY2024Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1625
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1198
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29243
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1198
CY2024Q3 us-gaap Cost Of Revenue
CostOfRevenue
132522
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
13416
us-gaap Cost Of Revenue
CostOfRevenue
825910
us-gaap Cost Of Revenue
CostOfRevenue
13416
CY2024Q3 us-gaap Gross Profit
GrossProfit
-130897
CY2023Q3 us-gaap Gross Profit
GrossProfit
-12218
us-gaap Gross Profit
GrossProfit
-796667
us-gaap Gross Profit
GrossProfit
-12218
CY2024Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3471939
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3578113
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12500713
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8911124
CY2024Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
3729091
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2929855
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
11125115
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
9016550
eyen Reacquisition Of License Rights
ReacquisitionOfLicenseRights
4864600
CY2024Q3 us-gaap Operating Expenses
OperatingExpenses
7201030
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
6507968
us-gaap Operating Expenses
OperatingExpenses
28490428
us-gaap Operating Expenses
OperatingExpenses
17927674
CY2024Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-7331927
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6520186
us-gaap Operating Income Loss
OperatingIncomeLoss
-29287095
us-gaap Operating Income Loss
OperatingIncomeLoss
-17939892
CY2024Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1184
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-348226
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-93394
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-157783
eyen Change In Fair Value Of Equity Consideration Payable
ChangeInFairValueOfEquityConsiderationPayable
-1240800
CY2024Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
602109
CY2023Q3 us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
679222
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1954768
us-gaap Interest Expense Nonoperating
InterestExpenseNonoperating
1691228
CY2024Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
44999
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
208901
us-gaap Investment Income Interest
InvestmentIncomeInterest
230804
us-gaap Investment Income Interest
InvestmentIncomeInterest
494944
CY2024Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-555926
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-818547
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-576558
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1354067
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-7887853
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7338733
us-gaap Net Income Loss
NetIncomeLoss
-29863653
us-gaap Net Income Loss
NetIncomeLoss
-19293959
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69558325
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69558325
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40139697
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40139697
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56476876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56476876
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38563074
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38563074
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
8999094
CY2024Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3194547
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
546232
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-10922101
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
1817772
CY2024Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1888829
CY2024Q2 eyen Stock Issued During Period Value Licensing Agreements
StockIssuedDuringPeriodValueLicensingAgreements
436809
CY2024Q2 eyen Stock Issued During Period Value Reacquisition Of Licensing Agreement
StockIssuedDuringPeriodValueReacquisitionOfLicensingAgreement
2322391
CY2024Q2 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
1676939
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
541056
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11053699
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
-2369903
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12348178
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2868000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2868000
CY2024Q3 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
1175883
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
452998
CY2024Q3 us-gaap Net Income Loss
NetIncomeLoss
-7887853
CY2024Q3 us-gaap Stockholders Equity
StockholdersEquity
3719303
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2868000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
17234565
CY2023Q1 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
3499592
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
819064
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-5739366
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
15813855
CY2023Q2 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
403120
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
27200
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
493632
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-6215860
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
10521947
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
10886114
CY2023Q3 eyen Stock Issued During Period Value Licensing Agreements
StockIssuedDuringPeriodValueLicensingAgreements
1000000
CY2023Q3 eyen Stock Issued At Market Offering During Period Value New Issues
StockIssuedAtMarketOfferingDuringPeriodValueNewIssues
97436
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1738700
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1738700
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
612969
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-7338733
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
15779733
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
1738700
us-gaap Net Income Loss
NetIncomeLoss
-29863653
us-gaap Net Income Loss
NetIncomeLoss
-19293959
us-gaap Share Based Compensation
ShareBasedCompensation
1540286
us-gaap Share Based Compensation
ShareBasedCompensation
1925665
eyen Change In Fair Value Of Equity Consideration Payable
ChangeInFairValueOfEquityConsiderationPayable
-1240800
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
830605
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
505684
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
552620
eyen Amortization Of Debt Discount
AmortizationOfDebtDiscount
497654
us-gaap Tangible Asset Impairment Charges
TangibleAssetImpairmentCharges
88251
us-gaap Inventory Write Down
InventoryWriteDown
769217
us-gaap Inventory Write Down
InventoryWriteDown
12218
eyen Provision For Returned Deferred Clinical Supplies
ProvisionForReturnedDeferredClinicalSupplies
400000
eyen Non Cash Expenses On Reacquisition Of License Rights
NonCashExpensesOnReacquisitionOfLicenseRights
2864600
eyen Non Cash Rent Expense
NonCashRentExpense
391028
eyen Non Cash Rent Expense
NonCashRentExpense
403362
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-836507
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-39035
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
13761
eyen Increase Decrease In License Fee And Expense Reimbursements Receivables
IncreaseDecreaseInLicenseFeeAndExpenseReimbursementsReceivables
-786772
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
-1272309
eyen Increase Decrease In Deferred Clinical Supply Costs
IncreaseDecreaseInDeferredClinicalSupplyCosts
1637756
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1051023
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
62514
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1148
us-gaap Increase Decrease In Security Deposits
IncreaseDecreaseInSecurityDeposits
1750
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-179232
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2255
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1781
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-371359
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-453567
us-gaap Increase Decrease In Other Accounts Payable And Accrued Liabilities
IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities
-307373
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-352836
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-411266
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24010082
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17514342
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161476
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2702361
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
1122945
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-161476
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-3825306
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
16139994
eyen Proceeds From Sale Of Common Stock And Warrants In Registered Direct Offering
ProceedsFromSaleOfCommonStockAndWarrantsInRegisteredDirectOffering
11977468
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1902987
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
1091354
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
6234402
eyen Proceeds From Issuance Of Common Stock At Market Offering
ProceedsFromIssuanceOfCommonStockAtMarketOffering
4123864
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
187033
eyen Payments Of Stock Issuance Costs At Market Offering
PaymentsOfStockIssuanceCostsAtMarketOffering
123716
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
27200
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
5000000
eyen Payments Of Debt Issuance Costs Related Party
PaymentsOfDebtIssuanceCostsRelatedParty
125982
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
3773746
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
609140
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
16510630
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
19178340
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-7660928
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2161308
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
14849057
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
22863520
CY2024Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7188129
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
20702212
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
1402147
us-gaap Interest Paid Capitalized
InterestPaidCapitalized
1194132
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
505050
eyen Purchase Of Insurance Premium Financed By Short Term Note Payable
PurchaseOfInsurancePremiumFinancedByShortTermNotePayable
609140
eyen Accrual For Intangible Assets Milestone Obligation
AccrualForIntangibleAssetsMilestoneObligation
2000000
eyen Reclassification Of Deferred Clinical Supply Costs To Inventories
ReclassificationOfDeferredClinicalSupplyCostsToInventories
2575652
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
us-gaap Escrow Deposit Disbursements Related To Property Acquisition1
EscrowDepositDisbursementsRelatedToPropertyAcquisition1
39573
eyen Original Issue Discount On Notes Payable
OriginalIssueDiscountOnNotesPayable
212500
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
2868000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1738700
us-gaap Stock Issued1
StockIssued1
1000000
eyen Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
2
us-gaap Stock Issued1
StockIssued1
436809
eyen Stock Issued Value Reacquisition Of Licensing Agreement
StockIssuedValueReacquisitionOfLicensingAgreement
2322391
eyen Issuance Of Common Stock Related To Vested Restricted Stock Units
IssuanceOfCommonStockRelatedToVestedRestrictedStockUnits
4
CY2024Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7200000
CY2024Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-175400000
us-gaap Net Income Loss
NetIncomeLoss
-29900000
us-gaap Net Income Loss
NetIncomeLoss
-19300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24000000.0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-17500000
CY2024Q3 us-gaap Treasury Stock Value
TreasuryStockValue
0
CY2023Q4 us-gaap Treasury Stock Value
TreasuryStockValue
5450118
CY2024Q3 us-gaap Cash Uninsured Amount
CashUninsuredAmount
6784903
CY2023Q4 us-gaap Cash Uninsured Amount
CashUninsuredAmount
14243870
CY2024Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
427217
CY2023Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
30683
CY2024Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
2540039
CY2023Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
79115
CY2024Q3 us-gaap Inventory Net
InventoryNet
2967256
CY2023Q4 us-gaap Inventory Net
InventoryNet
109798
CY2024Q3 us-gaap Inventory Write Down
InventoryWriteDown
100000
CY2023Q3 us-gaap Inventory Write Down
InventoryWriteDown
0.0
us-gaap Inventory Write Down
InventoryWriteDown
800000
us-gaap Inventory Write Down
InventoryWriteDown
0.0
CY2024Q1 eyen Inventory Write Down Adjustments To List Price
InventoryWriteDownAdjustmentsToListPrice
200000
CY2024Q2 eyen Inventory Write Down Short Dated Inventory To Net Realizable Value
InventoryWriteDownShortDatedInventoryToNetRealizableValue
500000
CY2024Q3 eyen Inventory Write Down Short Dated Inventory To Net Realizable Value
InventoryWriteDownShortDatedInventoryToNetRealizableValue
100000
CY2024Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7887853
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-7338733
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29863653
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-19293959
CY2024Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
69316561
CY2023Q3 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
39107338
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
56298569
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
38192414
CY2023Q3 us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
926225
us-gaap Incremental Common Shares Attributable To Call Options And Warrants
IncrementalCommonSharesAttributableToCallOptionsAndWarrants
305349
CY2024Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
241764
CY2023Q3 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
106134
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
178307
us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
65311
CY2024Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
69558325
CY2024Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
69558325
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
40139697
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
40139697
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
56476876
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
56476876
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38563074
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
38563074
CY2024Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2024Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.18
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.18
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.53
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.53
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.50
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.50
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38339419
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
18559192
CY2024Q3 us-gaap Prepaid Insurance
PrepaidInsurance
356214
CY2023Q4 us-gaap Prepaid Insurance
PrepaidInsurance
167338
CY2024Q3 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
288705
CY2023Q4 eyen Payroll Taxes Receivable
PayrollTaxesReceivable
500684
CY2024Q3 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
131606
CY2023Q4 eyen Prepaid General And Administrative Expenses
PrepaidGeneralAndAdministrativeExpenses
85938
CY2024Q3 eyen Prepaid Patent Expense
PrepaidPatentExpense
71073
CY2023Q4 eyen Prepaid Patent Expense
PrepaidPatentExpense
48409
CY2024Q3 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
54810
CY2023Q4 eyen Prepaid Conference Expenses Current
PrepaidConferenceExpensesCurrent
123556
CY2024Q3 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
48172
CY2023Q4 eyen Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
421056
CY2024Q3 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2023Q4 eyen Prepaid Rent And Security Deposit
PrepaidRentAndSecurityDeposit
18750
CY2024Q3 us-gaap Other Assets
OtherAssets
18424
CY2024Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
987754
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1365731
CY2024Q3 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1141884
CY2023Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1302997
CY2024Q3 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
514948
CY2023Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
355616
CY2024Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1656832
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1658613
CY2024Q3 eyen Accrued Intangible Asset Milestone Obligation
AccruedIntangibleAssetMilestoneObligation
2000000
CY2024Q3 eyen Accrued Settlement On Defective Clinical Supply
AccruedSettlementOnDefectiveClinicalSupply
250000
CY2023Q4 eyen Accrued Settlement On Defective Clinical Supply
AccruedSettlementOnDefectiveClinicalSupply
100000
CY2024Q3 eyen Accrued Clinical Studies Costs
AccruedClinicalStudiesCosts
121588
CY2024Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
79042
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
63028
CY2024Q3 eyen Credit Card Payable
CreditCardPayable
29502
CY2023Q4 eyen Credit Card Payable
CreditCardPayable
27193
CY2024Q3 eyen Accrued Franchise Tax
AccruedFranchiseTax
15000
CY2024Q3 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
13550
CY2023Q4 eyen Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
89872
CY2024Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
9404
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
7835
CY2024Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
2518086
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
287928
CY2024Q3 us-gaap Notes Payable Current
NotesPayableCurrent
10064637
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
635178
CY2024Q3 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
9429459
CY2023Q4 us-gaap Notes Payable Current
NotesPayableCurrent
5833333
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
503914
CY2023Q4 eyen Notes Payable Current Net Of Debt Discount Current Current Portion
NotesPayableCurrentNetOfDebtDiscountCurrentCurrentPortion
5329419
CY2024Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
2304166
CY2024Q3 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
163051
CY2024Q3 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
2141115
CY2023Q4 us-gaap Long Term Notes Payable
LongTermNotesPayable
9804167
CY2023Q4 us-gaap Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
846936
CY2023Q4 eyen Notes Payable Non Current Net Of Debt Discount Non Current Non Current Portion
NotesPayableNonCurrentNetOfDebtDiscountNonCurrentNonCurrentPortion
8957231
CY2020Q4 eyen Written Notice Period For Termination Of Agreement
WrittenNoticePeriodForTerminationOfAgreement
P90D
us-gaap Operating Lease Payments
OperatingLeasePayments
352836
us-gaap Operating Lease Payments
OperatingLeasePayments
411266
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
904437
CY2024Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M13D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M10D
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P3Y3M10D
CY2024Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.100
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
183092
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
675400
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
560996
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
214618
CY2024Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1634106
CY2024Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
193025
CY2024Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1441081
CY2024Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
604647
CY2024Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
836434
eyen Related Party Transaction Monthly Consulting Fee
RelatedPartyTransactionMonthlyConsultingFee
5000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
90000000
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
eyen Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
6000000.0
us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5630556
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4299401
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4451107
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3597670
CY2024Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
12348178
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7575757
CY2024Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7575757
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.66
CY2024Q3 eyen Class Of Warrant Or Right Number Of Additional Securities Called By Additional Warrants Or Rights
ClassOfWarrantOrRightNumberOfAdditionalSecuritiesCalledByAdditionalWarrantsOrRights
1749780
CY2024Q3 us-gaap Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
P6M
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.69
CY2024Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
4300000
CY2024Q3 eyen Placement Agent Fees
PlacementAgentFees
400000
CY2024Q3 us-gaap Legal Fees
LegalFees
300000
CY2024Q3 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
2900000
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
12850000
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.40
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5100000
CY2024Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
4500000
CY2024Q3 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
8630000
CY2024Q3 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
0.46
CY2024Q3 eyen Class Of Warrant Or Right Price Of Warrants Or Rights
ClassOfWarrantOrRightPriceOfWarrantsOrRights
0.4599
CY2024Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
0.0001
CY2024Q3 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4000000.0
CY2024Q3 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
3600000
CY2024Q3 us-gaap Share Price
SharePrice
0.68
CY2023Q3 us-gaap Share Price
SharePrice
1.97
CY2024Q3 us-gaap Share Price
SharePrice
0.68
CY2023Q3 us-gaap Share Price
SharePrice
1.97
CY2023Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10926554
CY2023Q4 eyen Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
2.28
eyen Class Of Warrant Or Right Granted
ClassOfWarrantOrRightGranted
18021190
eyen Class Of Warrant Or Right Granted Weighted Average Exercise Price
ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice
0.60
eyen Class Of Warrant Or Right New Repriced
ClassOfWarrantOrRightNewRepriced
-10386269
eyen Class Of Warrant Or Right Old Repriced Weighted Average Exercise Price
ClassOfWarrantOrRightOldRepricedWeightedAverageExercisePrice
2.25
eyen Class Of Warrant Or Right Old Repriced
ClassOfWarrantOrRightOldRepriced
10386269
eyen Class Of Warrant Or Right New Repriced Weighted Average Exercise Price
ClassOfWarrantOrRightNewRepricedWeightedAverageExercisePrice
0.69
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
28947744
CY2024Q3 eyen Class Of Warrant Or Right Outstanding Weighted Average Exercise Price
ClassOfWarrantOrRightOutstandingWeightedAverageExercisePrice
0.67
eyen Class Of Warrant Or Right Outstanding Weighted Average Remaining Life
ClassOfWarrantOrRightOutstandingWeightedAverageRemainingLife
P5Y1M6D
CY2024Q3 eyen Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
540285
CY2024Q3 eyen Class Of Warrant Or Right Exercisable Weighted Average Exercise Price
ClassOfWarrantOrRightExercisableWeightedAverageExercisePrice
2.96
eyen Class Of Warrant Or Right Exercisable Weighted Average Remaining Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
P1Y4M24D
CY2024Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
28947744
eyen Class Of Warrant Or Right Exercisable Weighted Average Remaining Life
ClassOfWarrantOrRightExercisableWeightedAverageRemainingLife
P1Y4M24D
CY2024Q3 eyen Class Of Warrant Or Right Exercisable
ClassOfWarrantOrRightExercisable
540285
CY2024Q3 us-gaap Share Based Compensation
ShareBasedCompensation
452998
CY2023Q3 us-gaap Share Based Compensation
ShareBasedCompensation
612969
us-gaap Share Based Compensation
ShareBasedCompensation
1540286
us-gaap Share Based Compensation
ShareBasedCompensation
1925665
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
106019
CY2023Q4 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
2.12
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
368886
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
0.65
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
106019
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedInPeriodWeightedAverageExercisePrice
2.12
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
368886
CY2024Q3 eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Non Vested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsNonVestedOutstandingWeightedAverageExercisePrice
0.65
eyen Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested Rs Us Undelivered Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedRSUsUndeliveredNumber
241764
eyen Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Vested Rs Us Undelivered Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsVestedRSUsUndeliveredWeightedAverageExercisePrice
2.17
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
6695042
us-gaap Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2
SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
P5Y9M18D
CY2024Q3 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
4022998
CY2024Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
CY2024Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2042227
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y9M18D
CY2024Q3 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.40
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0.79
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.70
CY2019Q2 us-gaap Defined Contribution Plan Employer Matching Contribution Percent Of Match
DefinedContributionPlanEmployerMatchingContributionPercentOfMatch
1
CY2019Q2 us-gaap Defined Contribution Plan Employers Matching Contribution Annual Vesting Percentage
DefinedContributionPlanEmployersMatchingContributionAnnualVestingPercentage
0.04
CY2024Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
56493
CY2023Q3 us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
46636
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
220682
us-gaap Defined Contribution Plan Maximum Annual Contributions Per Employee Amount
DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount
171800
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q2 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q3 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q2 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2024Q3 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
eyen-20240930_cal.xml Edgar Link unprocessable
0001410578-24-001894-index-headers.html Edgar Link pending
0001410578-24-001894-index.html Edgar Link pending
0001410578-24-001894.txt Edgar Link pending
0001410578-24-001894-xbrl.zip Edgar Link pending
eyen-20240930.xsd Edgar Link pending
eyen-20240930x10q.htm Edgar Link pending
eyen-20240930xex10d7.htm Edgar Link pending
eyen-20240930xex10d8.htm Edgar Link pending
eyen-20240930xex31d1.htm Edgar Link pending
eyen-20240930xex31d2.htm Edgar Link pending
eyen-20240930xex32d1.htm Edgar Link pending
eyen-20240930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
eyen-20240930_def.xml Edgar Link unprocessable
eyen-20240930_lab.xml Edgar Link unprocessable
eyen-20240930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
eyen-20240930x10q_htm.xml Edgar Link completed
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending